LY2606368

Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib shows potent anti-tumor activity.


Cat. No.: EX-A758	Purity:

	Chemical structure of LY2606368

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	507	in_stock
250mg	989	in_stock
500mg	1563	in_stock
1g	2606	in_stock
2g	4111	in_stock
3g	5028	in_stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	Prexasertib
CAS No.	1234015-52-1
Formula	C18H19N7O2
Mol Weight	365.3892
State	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. King C, et al. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Mol Cancer Ther. 2015 Sep;14(9):2004-1 [2]. Yin Y, et al. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017 Mar 1;7(3):473-483.
CoA	CoA of LY2606368

Smiles:	COC1=C(C2=CC(NC3=CN=C(C=N3)C#N)=NN2)C(OCCCN)=CC=C1


		Search